Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
Patients with steroid-refractory acute graft-versus-host disease (aGvHD) not tolerating/responding to ruxolitinib (RR-aGvHD) have a dismal prognosis. We retrospectively assessed real-world outcomes of RR-aGvHD treated with the random-donor allogeneic MSC preparation MSC-FFM, available via Hospital E...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
21 November 2023
|
| In: |
Journal of translational medicine
Year: 2023, Volume: 21, Pages: 1-11 |
| ISSN: | 1479-5876 |
| DOI: | 10.1186/s12967-023-04731-1 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12967-023-04731-1 Verlag, kostenfrei, Volltext: http://translational.medicine.biomedcentral.com/articles/10.1186/s12967-023-04731-1 
|
| Author Notes: | Halvard Bonig, Mareike Verbeek, Peter Herhaus, Krischan Braitsch, Gernot Beutel, Christoph Schmid, Nadine Müller, Gesine Bug, Michaela Döring, Arend von Stackelberg, Johanna Tischer, Francis Ayuk, Gerald Wulf, Udo Holtick, Lisa-Marie Pfeffermann, Bernd Jahrsdörfer, Hubert Schrezenmeier, Selim Kuci, Zyrafete Kuci, Anke Zens, Michael Tribanek, Robert Zeiser, Sabine Huenecke and Peter Bader |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1903859549 | ||
| 003 | DE-627 | ||
| 005 | 20250325052845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241001s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12967-023-04731-1 |2 doi | |
| 035 | |a (DE-627)1903859549 | ||
| 035 | |a (DE-599)KXP1903859549 | ||
| 035 | |a (OCoLC)1475314020 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bönig, Halvard |d 1967- |e VerfasserIn |0 (DE-588)120496100 |0 (DE-627)696726009 |0 (DE-576)29224973X |4 aut | |
| 245 | 1 | 0 | |a Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease |c Halvard Bonig, Mareike Verbeek, Peter Herhaus, Krischan Braitsch, Gernot Beutel, Christoph Schmid, Nadine Müller, Gesine Bug, Michaela Döring, Arend von Stackelberg, Johanna Tischer, Francis Ayuk, Gerald Wulf, Udo Holtick, Lisa-Marie Pfeffermann, Bernd Jahrsdörfer, Hubert Schrezenmeier, Selim Kuci, Zyrafete Kuci, Anke Zens, Michael Tribanek, Robert Zeiser, Sabine Huenecke and Peter Bader |
| 264 | 1 | |c 21 November 2023 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 01.10.2024 | ||
| 520 | |a Patients with steroid-refractory acute graft-versus-host disease (aGvHD) not tolerating/responding to ruxolitinib (RR-aGvHD) have a dismal prognosis. We retrospectively assessed real-world outcomes of RR-aGvHD treated with the random-donor allogeneic MSC preparation MSC-FFM, available via Hospital Exemption in Germany. MSC-FFM is provided as frozen cell dispersion for administration as i.v. infusion immediately after thawing, at a recommended dose of 1-2 million MSCs/kg body weight in 4 once-weekly doses. 156 patients, 33 thereof children, received MSC-FFM; 5% had Grade II, 40% had Grade III, and 54% had Grade IV aGvHD. Median (range) number of prior therapies was 4 (1-10) in adults and 7 (2-11) in children. The safety profile of MSC-FFM was consistent with previous reports for MSC therapies in general and MSC-FFM specifically. The overall response rate at Day 28 was 46% (95% confidence interval [CI] 36-55%) in adults and 64% (45-80%) in children; most responses were durable. Probability of overall survival at 6, 12 and 24 months was 47% (38-56%), 35% (27-44%) and 30% (22-39%) for adults, and 59% (40-74%), 42% (24-58%) and 35% (19-53%) for children, respectively (whole cohort: median OS 5.8 months). A recent real-world analysis of outcomes for 64 adult RR-aGvHD patients not treated with MSCs reports survival of 20%, 16% and 10% beyond 6, 12 and 24 months, respectively (median 28 days). Our data thus suggest effectiveness of MSC-FFM in RR-aGvHD. | ||
| 700 | 1 | |8 1\p |a Verbeek, Mareike |d 1976- |e VerfasserIn |0 (DE-588)124945503 |0 (DE-627)368956814 |0 (DE-576)294582185 |4 aut | |
| 700 | 1 | |8 2\p |a Herhaus, Peter |d 1984- |e VerfasserIn |0 (DE-588)1181824915 |0 (DE-627)166239523X |4 aut | |
| 700 | 1 | |a Braitsch, Krischan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Beutel, Gernot |e VerfasserIn |4 aut | |
| 700 | 1 | |8 3\p |a Schmid, Christoph |e VerfasserIn |0 (DE-588)1176729551 |0 (DE-627)1047755327 |0 (DE-576)516777637 |4 aut | |
| 700 | 1 | |a Müller, Nadine Zoé |d 1981- |e VerfasserIn |0 (DE-588)141457082 |0 (DE-627)627795722 |0 (DE-576)323590365 |4 aut | |
| 700 | 1 | |8 4\p |a Bug, Gesine |e VerfasserIn |0 (DE-588)1055034617 |0 (DE-627)792579704 |0 (DE-576)411120158 |4 aut | |
| 700 | 1 | |8 5\p |a Döring, Michaela |e VerfasserIn |0 (DE-588)139146520 |0 (DE-627)703224409 |0 (DE-576)310442982 |4 aut | |
| 700 | 1 | |8 6\p |a Stackelberg, Arend von |d 1965- |e VerfasserIn |0 (DE-588)120029693 |0 (DE-627)696315793 |0 (DE-576)292003900 |4 aut | |
| 700 | 1 | |8 7\p |a Tischer, Johanna |d 1968- |e VerfasserIn |0 (DE-588)1147421811 |0 (DE-627)1006156283 |0 (DE-576)495793299 |4 aut | |
| 700 | 1 | |8 8\p |a Ayuk, Francis |d 1973- |e VerfasserIn |0 (DE-588)1028065175 |0 (DE-627)730259161 |0 (DE-576)375553053 |4 aut | |
| 700 | 1 | |8 9\p |a Wulf, Gerald |d 1966- |e VerfasserIn |0 (DE-588)172647010 |0 (DE-627)697580830 |0 (DE-576)133505766 |4 aut | |
| 700 | 1 | |8 10\p |a Holtick, Udo |d 1973- |e VerfasserIn |0 (DE-588)12908011X |0 (DE-627)388711388 |0 (DE-576)297483331 |4 aut | |
| 700 | 1 | |a Pfeffermann, Lisa-Marie |e VerfasserIn |4 aut | |
| 700 | 1 | |8 11\p |a Jahrsdörfer, Bernd |d 1971- |e VerfasserIn |0 (DE-588)122038789 |0 (DE-627)081698291 |0 (DE-576)293061661 |4 aut | |
| 700 | 1 | |8 12\p |a Schrezenmeier, Hubert |e VerfasserIn |0 (DE-588)111741904 |0 (DE-627)682876747 |0 (DE-576)356239551 |4 aut | |
| 700 | 1 | |8 13\p |a Kuci, Selim |e VerfasserIn |0 (DE-588)1194592465 |0 (DE-627)1676818545 |4 aut | |
| 700 | 1 | |a Kuci, Zyrafete |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zens, Anke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tribanek, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |8 14\p |a Zeiser, Robert |d 1975- |e VerfasserIn |0 (DE-588)12346000X |0 (DE-627)082568081 |0 (DE-576)293718016 |4 aut | |
| 700 | 1 | |a Huenecke, Sabine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bader, Peter |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of translational medicine |d London : BioMed Central, 2003 |g 21(2023), Artikel-ID 837, Seite 1-11 |h Online-Ressource |w (DE-627)369084136 |w (DE-600)2118570-0 |w (DE-576)107015994 |x 1479-5876 |7 nnas |a Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g elocationid:837 |g pages:1-11 |g extent:11 |a Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease |
| 787 | 0 | 8 | |i Errata |a Bönig, Halvard, 1967 - |t Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease |d 2024 |w (DE-627)1903860342 |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12967-023-04731-1 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://translational.medicine.biomedcentral.com/articles/10.1186/s12967-023-04731-1 |x Verlag |z kostenfrei |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 2\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 3\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 4\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 5\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 6\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 7\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 8\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 9\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 10\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 11\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 12\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 13\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 14\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20241001 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 141457082 |a Müller, Nadine Zoé |m 141457082:Müller, Nadine Zoé |p 7 | ||
| 999 | |a KXP-PPN1903859549 |e 4585074740 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 01.10.2024"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1903859549","language":["eng"],"person":[{"family":"Bönig","given":"Halvard","display":"Bönig, Halvard","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Verbeek","given":"Mareike","display":"Verbeek, Mareike","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Peter","family":"Herhaus","role":"aut","display":"Herhaus, Peter","roleDisplay":"VerfasserIn"},{"given":"Krischan","family":"Braitsch","role":"aut","display":"Braitsch, Krischan","roleDisplay":"VerfasserIn"},{"family":"Beutel","given":"Gernot","display":"Beutel, Gernot","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Schmid, Christoph","roleDisplay":"VerfasserIn","role":"aut","family":"Schmid","given":"Christoph"},{"role":"aut","display":"Müller, Nadine Zoé","roleDisplay":"VerfasserIn","given":"Nadine Zoé","family":"Müller"},{"display":"Bug, Gesine","roleDisplay":"VerfasserIn","role":"aut","family":"Bug","given":"Gesine"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Döring, Michaela","given":"Michaela","family":"Döring"},{"role":"aut","display":"Stackelberg, Arend von","roleDisplay":"VerfasserIn","given":"Arend von","family":"Stackelberg"},{"roleDisplay":"VerfasserIn","display":"Tischer, Johanna","role":"aut","family":"Tischer","given":"Johanna"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Ayuk, Francis","given":"Francis","family":"Ayuk"},{"family":"Wulf","given":"Gerald","roleDisplay":"VerfasserIn","display":"Wulf, Gerald","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Holtick, Udo","given":"Udo","family":"Holtick"},{"family":"Pfeffermann","given":"Lisa-Marie","display":"Pfeffermann, Lisa-Marie","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Jahrsdörfer, Bernd","roleDisplay":"VerfasserIn","role":"aut","family":"Jahrsdörfer","given":"Bernd"},{"role":"aut","display":"Schrezenmeier, Hubert","roleDisplay":"VerfasserIn","given":"Hubert","family":"Schrezenmeier"},{"family":"Kuci","given":"Selim","roleDisplay":"VerfasserIn","display":"Kuci, Selim","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Kuci, Zyrafete","given":"Zyrafete","family":"Kuci"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Zens, Anke","given":"Anke","family":"Zens"},{"roleDisplay":"VerfasserIn","display":"Tribanek, Michael","role":"aut","family":"Tribanek","given":"Michael"},{"family":"Zeiser","given":"Robert","display":"Zeiser, Robert","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Sabine","family":"Huenecke","role":"aut","roleDisplay":"VerfasserIn","display":"Huenecke, Sabine"},{"roleDisplay":"VerfasserIn","display":"Bader, Peter","role":"aut","family":"Bader","given":"Peter"}],"title":[{"title":"Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease","title_sort":"Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease"}],"physDesc":[{"extent":"11 S."}],"relHost":[{"origin":[{"publisher":"BioMed Central","dateIssuedKey":"2003","dateIssuedDisp":"2003-","publisherPlace":"London"}],"id":{"eki":["369084136"],"zdb":["2118570-0"],"issn":["1479-5876"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Journal of translational medicine","title_sort":"Journal of translational medicine"}],"pubHistory":["1.2003 -"],"part":{"pages":"1-11","year":"2023","extent":"11","volume":"21","text":"21(2023), Artikel-ID 837, Seite 1-11"},"note":["Gesehen am 22.06.20"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host diseaseJournal of translational medicine","language":["eng"],"recId":"369084136"}],"name":{"displayForm":["Halvard Bonig, Mareike Verbeek, Peter Herhaus, Krischan Braitsch, Gernot Beutel, Christoph Schmid, Nadine Müller, Gesine Bug, Michaela Döring, Arend von Stackelberg, Johanna Tischer, Francis Ayuk, Gerald Wulf, Udo Holtick, Lisa-Marie Pfeffermann, Bernd Jahrsdörfer, Hubert Schrezenmeier, Selim Kuci, Zyrafete Kuci, Anke Zens, Michael Tribanek, Robert Zeiser, Sabine Huenecke and Peter Bader"]},"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"21 November 2023"}],"id":{"doi":["10.1186/s12967-023-04731-1"],"eki":["1903859549"]}} | ||
| SRT | |a BOENIGHALVREALWORLDD2120 | ||